ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "juvenile dermatomyositis"

  • Abstract Number: 1347 • 2018 ACR/ARHP Annual Meeting

    A Semi-Quantitative Whole Body Magnetic Resonance Imaging Assessment Tool to Define Musculoskeletal Abnormalities in Patients with Idiopathic Inflammatory Myopathies

    Sara Faghihi-Kashani1, Lisa G. Rider2, David Bluemke3, Ashkan Malayeri4, Evrim Turkbey4, Joseph Shrader5, John McGrath6, Elizabeth Jones7, Jamie Marco8, Frederick W. Miller9 and Adam Schiffenbauer10, 1Environmental Autoimmunity Group, National Institute of Environmental Health, Bethesda, MD, 2Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3Department of Radiology, University of Wisconsin School of Medicine and Public Health, Madison, WI, 4Radiology and Imaging Sciences, National Institutes of Health, Bethesda, MD, 5Rehabilitation Medicine, National Institutes of Health, Bethesda, MD, 6Social and Scientific Systems, Inc., Durham, NC, 7Radiology and Imaging Sciences, National Institutes of Health Clinical Center, Bethesda, MD, 8Radiology and Imaging Sciences National Institutes of Health, Bethesda, MD, 9Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 10NIEHS, NIH, Bethesda, MD

    Background/Purpose: There is a lack of standardized methodology for assessing whole body MRI (WBMRI) in idiopathic inflammatory myopathy (IIM) patients. This leads to difficulty in…
  • Abstract Number: 1402 • 2018 ACR/ARHP Annual Meeting

    The Relationship of Pain, Fatigue and Emotional Distress with Quality of Life in Juvenile Myositis

    Kyle J. Fahey1, Elizabeth L. Gray2, Rowland W. Chang3, David Cella4, Lauren M. Pachman5 and Kaveh Ardalan6, 1Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Preventive Medicine, Medicine, and Physical Medicine & Rehabilitation, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Departments of Medical Social Sciences, Neurology, Pediatrics, Preventive Medicine, and Psychiatry and Behavioral Sciences,, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 6Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile Myositis (JM) is an autoimmune disease that negatively impacts quality of life (QoL) outcomes via muscle weakness and vasculopathic rashes. The relative contribution…
  • Abstract Number: 1851 • 2018 ACR/ARHP Annual Meeting

    Physical Function Trajectories in Children with Juvenile Myositis

    Kaveh Ardalan1, Elizabeth L. Gray2, Julia (Jungwha) Lee2, Madison L. Wolfe3, Gabrielle A. Morgan4 and Lauren M. Pachman5, 1Departments of Pediatrics and Medical Social Sciences, Division of Rheumatology, Northwestern University Feinberg School of Medicine/Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 2Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Creighton University School of Medicine, Omaha, NE, 4Cure JM Program of Excellence in Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 5Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile myositis (JM) is an inflammatory disease that causes muscle weakness, skin rashes, and significant deconditioning. Little is known about long-term resolution of physical…
  • Abstract Number: 2031 • 2018 ACR/ARHP Annual Meeting

    Dysregulated NK Cell PLC

    Allison A. Throm1, Joshua B. Alinger1, Lauren M. Pachman2 and Anthony R. French3, 1Pediatrics, Washington University St Louis, St Louis, MO, 2Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Pediatric Rheumatology, Washington University St Louis, Saint Louis, MO

    Background/Purpose: Juvenile dermatomyositis (JDM) is a debilitating pediatric autoimmune disease manifesting with characteristic rash and proximal muscle weakness. We investigated signaling abnormalities in immune cell…
  • Abstract Number: 2285 • 2018 ACR/ARHP Annual Meeting

    Factors Associated with Corticosteroid Discontinuation, Complete Clinical Response and Remission in Patients with Juvenile Dermatomyositis

    Takayuki Kishi1,2, William Warren-Hicks3, Nastaran Bayat1, Ira Targoff4, Terri H Finkel5, Ellen Goldmuntz6, Michael Henrickson7, Bianca Lang8, Andrew Mammen9, Lauren M. Pachman10, Murray Passo11, Terrance P. O'Hanlon1, Frederick W. Miller1, Michael Ward9 and Lisa G. Rider1, 1Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 2Department of Pediatrics, Tokyo Women's Medical University, Tokyo, Japan, 3EcoStat, Inc., Mebane, NC, 4VA Medical Center, University of Oklahoma Health Sciences Center and Oklahoma Medical Research Foundation, Oklahoma City, OK, 5Department of Pediatrics, Nemours Children's Health System/ Nemours Children's Hospital, Orlando, FL, 6NIAID, NIH, Bethesda, MD, 7Division of Rheumatology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH, 8Department of Pediatrics, IWK Health Centre and Dalhousie University, Halifax, NS, Canada, 9National Institute of Arthritis and Musculoskeletal and Skin Diseases, National Institutes of Health, Bethesda, MD, 10Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 11Division of Rheumatology PTD, Medical University of South Carolina, Charleston, SC

    Background/Purpose: We examined patients in a large juvenile dermatomyositis (JDM) registry for frequency of and factors associated with final corticosteroid discontinuation (Steroid DC), complete clinical…
  • Abstract Number: 2336 • 2017 ACR/ARHP Annual Meeting

    Expression of Myxovirus-Resistance Protein a: A Possible Marker of Muscular Disease Activity in Juvenile Dermatomyositis

    Sirisucha Soponkanaporn1, Claire Deakin2, Lucy Marshall2, Cerise Johnson2, Peter Schutz1 and Lucy R Wedderburn2, 1Infection Inflammation and Rheumatology Section, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, 2Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom

    Background/Purpose: Juvenile dermatomyositis (JDM) is a chronic autoimmune myopathy characterized by proximal muscle weakness and typical skin rashes. Type I interferon (IFN) gene expression in…
  • Abstract Number: 2337 • 2017 ACR/ARHP Annual Meeting

    Novel Serum Broad-Based Proteomic Discovery Analysis Identifies Proteins and Pathways Dysregulated in Juvenile Dermatomyositis (JDM) and Myositis Autoantibody Groups

    Hanna Kim1, Angélique Biancotto2, Foo Cheung3, Terrance P. O'Hanlon4, Ira N. Targoff5, Yan Huang6, Frederick W Miller4, Raphaela Goldbach-Mansky6 and Lisa G Rider4, 1Pediatric Translational Research Branch, NIAMS/NIH, Bethesda, MD, 2Center for Human Immunology, Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 3Center for Human Immunology Autoimmunity and Inflammation (CHI), NHLBI, NIH, Bethesda, MD, 4Environmental Autoimmunity Group, NIEHS, NIH, Bethesda, MD, 5VA Medical Center, University of Oklahoma Health Sciences Center, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Translational Autoinflammatory Disease Studies (TADS), Laboratory of Clinical Investigation and Microbiology (LCIM), NIAID/NIH, Bethesda, MD

    Background/Purpose: Juvenile dermatomyositis (JDM) is a complex heterogeneous autoimmune disease.  Myositis-specific autoantibodies (MSAs), present in up to 80% of JDM patients, help define distinct phenotypes…
  • Abstract Number: 2342 • 2017 ACR/ARHP Annual Meeting

    Transcriptomic Analysis Reveals Mitochondrial and Monocyte Dysfunctions Are Linked to the Interferonopathy of Juvenile Dermatomyositis

    Claire Deakin1, Elizabeth Rosser1, Lucy Marshall1, Meredyth Wilkinson2, Aziza Khabbush3, Stefania Simou1, Georg Otto3, Stefanie Dowle3, Daniel Kelberman3, Simon Yona2, Simon Eaton3 and Lucy R Wedderburn1, 1Infection, Immunity and Inflammation Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom, 2Division of Medicine, University College London, London, United Kingdom, 3Genetics and Genomic Medicine Programme, UCL Great Ormond Street Institute of Child Health, University College London, United Kingdom, London, United Kingdom

    Background/Purpose: Although type I interferon (IFN1) and endoplasmic reticulum (ER) stress have been implicated in pathogenesis of juvenile dermatomyositis (JDM), little else is known about…
  • Abstract Number: 2895 • 2017 ACR/ARHP Annual Meeting

    Predictors of Hospitalization, Length of Stay and Costs of Care Among Children with Juvenile Dermatomyositis in the United States

    Michael C. Kwa1, Jonathan I. Silverberg2 and Kaveh Ardalan3,4, 1Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile dermatomyositis (JDM) is a rare autoimmune disease that causes significant morbidity and quality of life impairment. Little is known about JDM inpatient burden…
  • Abstract Number: 2960 • 2017 ACR/ARHP Annual Meeting

    Cardiovascular and Cerebrovascular Comorbidities of Juvenile Dermatomyositis in United States Children

    Jonathan I. Silverberg1, Lauren Kwa2, Michael C. Kwa2, Anne Laumann2 and Kaveh Ardalan3,4, 1Dermatology, Preventive Medicine and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, 3Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 4Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile dermatomyositis (JDM) is an autoimmune disease that causes vasculopathy and inflammation of skin and muscles. Previous studies in adult dermatomyositis suggest increased risks…
  • Abstract Number: 2961 • 2017 ACR/ARHP Annual Meeting

    Body Composition and Myokine Levels in Juvenile Dermatomyositis and Associations with Physical Function

    Birgit Nomeland Witczak1, Kristin Godang2, Jens Bollerslev2,3, Thomas Schwartz4,5, Berit Flatø3,6, Ivar Sjaastad3,4,7 and Helga Sanner6,8, 1Oslo University Hospital, Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 2Section of Specialized Endocrinology, Department of Endocrinology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 3Institute for Clinical Medicine, University of Oslo, Oslo, Norway, Oslo, Norway, 4Institute for Experimental Medical Research, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 5Department of Infectious Diseases, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 6Department of Rheumatology, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway, 7Department of Cardiology, Oslo University Hospital, Oslo, Norway, Oslo, Norway, 8Norwegian National Advisory Unit on Rheumatic Diseases in Children and Adolescents, Oslo University Hospital, Rikshospitalet, Oslo, Norway, Oslo, Norway

    Background/Purpose: JDM presents with proximal muscle weakness and atrophy is frequent. Still, body composition (BC) in JDM has not been widely studied, but is known…
  • Abstract Number: 852 • 2017 ACR/ARHP Annual Meeting

    RNAseq Detection of Gene Dysregulation in PBMCs from Juvenile Dermatomyositis, Positive for p155/140 Myositis Specific Antibody

    Chiang-Ching Huang1, Victoria Hans2, Dong Xu3, Megan L. Curran4,5, Gabrielle A. Morgan6, Elisha D.O. Roberson7 and Lauren M. Pachman8,9, 1Biostatistics, Joseph J. Zilber School of Public Health,, Milwaukee, WI, 2CureJM Center of Excellence, Stanly Manne Research Center, Chicago, IL, 3Pediatric Rheumatology, Stanley Manne Research Center, Chicago, IL, 4Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Division of Rheumatology, Ann and Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 6Cure JM Program of Excellence in Myositis Research, Chicago, IL, 7Depts. of Medicine and Genetics, Division of Rheumatology, Washington University, St. Louis, MO, 8Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 9Pediatric Rheumatology, Northwestern University Feinberg School of Medicine, Chicago, IL

    Background/Purpose: Children with Juvenile Dermatomyositis (JDM) have variable responses to the available immunosuppressive drugs, with less than optimal outcomes, making it essential to characterize their…
  • Abstract Number: 1274 • 2017 ACR/ARHP Annual Meeting

    Anti-MDA5 Autoantibodies Associated with Juvenile Dermatomyositis Constitute a Distinct Phenotype in North America 

    Gulnara Mamyrova1, Takayuki Kishi2, Ira N Targoff3, Rodolfo V Curiel4, Frederick W Miller2 and Lisa G Rider2, 1Rheumatology, George Washington University School of Medicine and Health Sciences, Washington, DC, 2Environmental Autoimmunity Group, National Institute of Environmental Health Sciences, National Institutes of Health, Bethesda, MD, 3VA Medical Center, University of Oklahoma Health Sciences Center, and Oklahoma Medical Research Foundation, Oklahoma City, OK, 4George Washington University School of Medicine and Health Sciences, Washington, DC

    Background/Purpose: Anti-MDA5 autoantibodies (Abs) have been associated with clinically amyopathic and classic dermatomyositis (DM), with rapidly progressive interstitial lung disease (ILD) and poor prognosis in…
  • Abstract Number: 1277 • 2017 ACR/ARHP Annual Meeting

    Longitudinal Predictors of Physical Function in Juvenile Myositis

    Kaveh Ardalan1,2, Hannah L. Palac3,4, Julia (Jungwha) Lee4, Madison Wolfe5,6, Gabrielle A. Morgan7,8 and Lauren M. Pachman9, 1Departments of Pediatrics and Medical Social Sciences, Northwestern University Feinberg School of Medicine, Chicago, IL, 2Division of Rheumatology, Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL, 3Abbvie, Inc, Chicago, IL, 4Preventive Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, 5Division of Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 6Pediatrics, Northwestern University Feinberg School of Medicine, Chicago, IL, 7Cure JM Program of Excellence in Myositis Research, Chicago, IL, 8Rheumatology, Ann & Robert H. Lurie Children's Hospital of Chicago, Chicago, IL, 9Cure JM Program of Excellence in Juvenile Myositis Research, Stanley Manne Children’s Research Institute, affiliated with Ann & Robert H. Lurie Children’s Hospital of Chicago, Chicago, IL

    Background/Purpose: Juvenile myositis (JM) is marked by skin rashes, proximal muscle weakness, and deconditioning causing potentially severe disability. Studies examining long-term physical function in JM…
  • Abstract Number: 1279 • 2017 ACR/ARHP Annual Meeting

    Risk Factors for Achieving a Drug-Free Remission in Patients with Juvenile Dermatomyositis

    Tomokazu Nagakura1, Takuma Ito2, Masateru Kusuda2, Tuyoshi Yamatou2, Tomohiro Kubota2, Yuuichi Yamasaki2, Yukiko Nonaka2, Tomoko Takezaki2, Harumi Akaike3, Yasuhito Nerome2, Hiroyuki Imanaka2 and Syuji Takei4, 1Pediatrics, The Holy Mother of Grace Hospital Home for Children and Persons with Severe Motor and Intellectual Disabilities, Usuki, Japan, Usuki, Japan, 2Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, 3Department of Pediatrics, Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshima, Japan, 4Department of Pediatrics, Kagoshima University Graduate School of Medical and Dental Sciences, Kagoshima, Japan, Kagoshma, Japan

    Background/Purpose: Juvenile dermatomyositis (JDM) is the most common idiopathic inflammatory myopathy in children. Approximately one-third of JDM patients attain drug-free remission (DFR) without relapse; however,…
  • « Previous Page
  • 1
  • 2
  • 3
  • 4
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology